ArticleJournal of cellular and molecular medicine2026
Mitophagy-Oxidative Stress Molecular Subtypes Define an Immunosuppressive Ecosystem and Vulnerabilities in Glioblastoma.
Article in Journal of cellular and molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma (GBM) is an aggressive brain tumour with an immunosuppressive environment and poor prognosis; however, the roles of mitophagy and oxidative stress in its prognosis remain underexplored. This study analysed multi-omics data from TCGA-GBM (n = 168) and two GEO cohorts (GSE43378, n = 50; GSE147352, n = 85), compiling 603 mitophagy and oxidative stress-related genes. Unsupervised consensus clustering identified molecular subtypes, and prognostic genes were found via univariate Cox regression, leading to a refined gene signature using LASSO. The tumour immune microenvironment was characterized with ESTIMATE, CIBERSORT, and ssGSEA, while immunotherapy response was predicted using TIDE and IPS. Drug sensitivity was evaluated with GDSC and CTRP data, and a clinical nomogram integrating the gene signature and clinical variables was constructed and validated. Two molecular subtypes, C1 and C2, showed different prognoses (HR = 0.64, p = 0.011) and immune profiles. A 7-gene signature indicated high-risk patients had worse survival (p < 0.001) and an immunosuppressive environment. The risk score correlated with anti-PD-1 response (p < 0.05) and predicted therapy sensitivity. The signature was an independent prognostic factor (HR = 3.37, p < 0.001), and the nomogram accurately predicted survival at 1, 3, and 5 years. An innovative prognostic signature from mitophagy and oxidative stress genes stratifies GBM patients, characterizes the immunosuppressive microenvironment, and identifies therapeutic vulnerabilities for personalized treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.